A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study-Reference-Cited by-同舟云学术

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study

Published:2004-11-23 Issue:12 Volume:91 Page:1996-2004
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Gridelli C, ,Gallo C,Di Maio M,Barletta E,Illiano A,Maione P,Salvagni S,Piantedosi F V,Palazzolo G,Caffo O,Ceribelli A,Falcone A,Mazzanti P,Brancaccio L,Capuano M A,Isa L,Barbera S,Perrone F

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6602241.pdf

Reference32 articles.

1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85: 365–376

2. American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14: 671–679

3. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M (1994) The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 30A: 635–642

4. Cox DR (1972) Regression models and life tables. J Roy Stat Soc B 34: 187–220

5. Dancey J, Shepherd FA, Richard J, Gralla RJ, Kim YS (2004) Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 43: 183–194

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes in patients with KRAS G12C–mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond;Lung Cancer;2023-07

2. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2023-04

3. Chemotherapy for Lung Cancer;Medical Radiology;2022

4. Factors affecting the efficacy and safety of docetaxel combined with platinum in the treatment of advanced non-small cell lung cancer;Expert Review of Clinical Pharmacology;2021-09-24

5. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial;EClinicalMedicine;2021-07